



Health, Seniors and Long-Term Care
Public Health
300 Carlton Street
Winnipeg, Manitoba Canada R3B 3M9

August 13, 2026

Re: Update – Use of Lentocilin™ for all clients requiring syphilis treatment with long-acting penicillin G

Dear Health Care Provider:

The national shortage of long-acting penicillin G (Bicillin® L-A) **has been extended with an estimated end date of February 26, 2027**. Manitoba has procured additional amounts of an alternative product for syphilis treatment under a Health Canada authorized temporary import: Lentocilin S 1200™ (benzathine penicillin G, 1.2 million units) powder and diluent for suspension and injection, manufactured and marketed in Portugal by Laboratórios Atral S.A.

Lentocilin™ can now be used for ALL clients requiring syphilis treatment with benzathine penicillin G, as described in the syphilis protocol <https://www.gov.mb.ca/health/publichealth/cdc/protocol/syphilis.pdf>.

However, as there are supply constraints, **sites will only be permitted to order approximately one month's supply at a time (with some exceptions for rural/remote sites in winter)**. Sites are no longer required to pre-approve orders for Lentocilin™ by email, but unusually large orders may be adjusted. **Please use the updated version of the STI Medication Order Form, available at <https://www.gov.mb.ca/health/publichealth/cdc/protocol/form11.pdf>.**

Lentocilin™ has the same active ingredient, strength (benzathine penicillin G, 1.2 million units) and route of administration (intramuscular) as Bicillin® L-A. However, Lentocilin™ has a different formulation, dosage form, and reconstitution requirement than Bicillin® L-A. Supplies for the reconstitution and administration of Lentocilin™, along with printed guidance will be provided with the product. For additional information on reconstitution and administration of Lentocilin™ see <https://www.gov.mb.ca/health/publichealth/cdc/docs/lentocilin-syphilis-treatment.pdf>.

Health Canada has issued Health Product Risk Communication (HPRC) for Foreign-Labelled Drug Products for Exceptional Importation and Supply. You may access the HPRC information on Lentocilin™ at <https://septalife.com/posts/resources/>.

Providers reporting the administration of Lentocilin™ on the **STBBI Provider Report Form** (https://www.gov.mb.ca/health/publichealth/surveillance/docs/mhsu_6781.pdf) should enter as Benzathine Penicillin G 2.4 million units but specify “Lentocilin” in the “Other Treatment” text box. This allows Lentocilin™ and Bicillin® to be distinguished in eChart.

A limited amount of Bicillin® L-A has been retained for patients requiring syphilis treatment and with contraindications to Lentocilin™ (e.g. hypersensitivity or anaphylactic reaction to soy products or lidocaine) and is available on a case-by-case basis. Bicillin® L-A requests must be submitted to STBBI@gov.mb.ca for approval prior to ordering.

Manitoba Health, Seniors, and Long-Term Care will provide further updates as new information becomes available and when normal Bicillin® L-A supply is restored. If you have any questions about the supply of Bicillin® L-A in Manitoba or the alternative Lentocilin™, please email STBBI@gov.mb.ca.

Please share this information with all relevant colleagues in your facility.

Sincerely,

“Original signed by”

Richard Baydack, PhD
Executive Director
Communicable Disease Prevention and Control

“Original signed by”

Carol Kurbis, MD, FRCPC
Medical Officer of Health
Communicable Disease Prevention and Control